{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:45:37Z","timestamp":1786977937766,"version":"build-2736575974"},"reference-count":9,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T00:00:00Z","timestamp":1783814400000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["IJU Case Reports"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Immune\u2010related encephalopathy is a rare neurological adverse event associated with immune checkpoint inhibitors. Neuroimaging and cerebrospinal fluid findings are often unremarkable, making the diagnosis challenging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Presentation<\/jats:title>\n                    <jats:p>A 70\u2010year\u2010old man with advanced clear cell renal cell carcinoma (RCC) was considered unresectable because of suspected adjacent organ invasion and high surgical risk. Therefore, pembrolizumab plus lenvatinib therapy was initiated, but 6\u2009days later, he developed confusion, speech difficulty, and gait disturbance. Blood tests, whole\u2010body computed tomography (CT), contrast\u2010enhanced brain CT, contrast\u2010enhanced brain magnetic resonance imaging (MRI), electroencephalography, and cerebrospinal fluid examination showed no significant abnormalities. After excluding other causes, grade 3 immune\u2010related encephalopathy was suspected. Pembrolizumab and Lenvatinib were discontinued and high\u2010dose corticosteroids were started, leading to subsequent neurological improvement without residual deficits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Immune\u2010related encephalopathy may occur early after pembrolizumab therapy. Early recognition and prompt steroid treatment are essential for a favorable neurological recovery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/iju5.70227","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T05:32:36Z","timestamp":1783920756000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Rare Case of Suspected Immune\u2010Related Encephalopathy Following Pembrolizumab Plus Lenvatinib Therapy for Renal Cell Carcinoma"],"prefix":"10.1002","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7799-6765","authenticated-orcid":false,"given":"Yuina","family":"Nagao","sequence":"first","affiliation":[{"name":"Department of Urology Tokushima Prefectural Central Hospital  Tokushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6204-0866","authenticated-orcid":false,"given":"Kyotaro","family":"Fukuta","sequence":"additional","affiliation":[{"name":"Department of Urology Tokushima Prefectural Central Hospital  Tokushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8027-2716","authenticated-orcid":false,"given":"Yuichiro","family":"Atagi","sequence":"additional","affiliation":[{"name":"Department of Urology Tokushima Prefectural Central Hospital  Tokushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Ozaki","sequence":"additional","affiliation":[{"name":"Department of Urology Tokushima Prefectural Central Hospital  Tokushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Department of Urology Tokushima Prefectural Central Hospital  Tokushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Neurology Tokushima Prefectural Central Hospital  Tokushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Nakanishi","sequence":"additional","affiliation":[{"name":"Department of Urology Tokushima Prefectural Central Hospital  Tokushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Izaki","sequence":"additional","affiliation":[{"name":"Department of Urology Tokushima Prefectural Central Hospital  Tokushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8974-9218","authenticated-orcid":false,"given":"Junya","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Department of Urology Tokushima University Graduate School of Biomedical Sciences  Tokushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,12]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8865054"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.08.007"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.2668"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8111777"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2019.07.001"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.55729\/2000-9666.1091"},{"key":"e_1_2_10_9_1","first-page":"173","article-title":"Case Report of Delayed Encephalopathy From Pembrolizumab","volume":"124","author":"Kotsis C.","year":"2025","journal-title":"WMJ"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0186"}],"container-title":["IJU Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/iju5.70227","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/iju5.70227","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/iju5.70227","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T06:46:47Z","timestamp":1785134807000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/iju5.70227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1002\/iju5.70227"],"URL":"https:\/\/doi.org\/10.1002\/iju5.70227","archive":["Portico"],"relation":{},"ISSN":["2577-171X","2577-171X"],"issn-type":[{"value":"2577-171X","type":"print"},{"value":"2577-171X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2026-03-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70227"}}